Tetsu Yung
Director of JAPAC Strategy
Building JAPAC strategy for Glafabra to advance durable, cell-based therapy for Fabry disease patients
Posts (1)
- 1
Disclosures
© 2026 BioTech Social Inc. (“BSI”). This website and related services are provided by BSI and BioTech Funding Portal LLC (“BFP”), a wholly owned subsidiary of BSI (collectively, “BioTech Social”). Certain regulated crowdfunding services and offerings available through this website are operated by BFP, while other content, features, and services may be provided, maintained, or supervised by BSI.
BFP is a FINRA member funding portal (FPRD #334156) registered with the U.S. Securities and Exchange Commission (“SEC”). Through BFP, eligible issuers may conduct offerings pursuant to Regulation Crowdfunding, and persons 18 years of age or older may review and invest in such offerings.
Offerings conducted by life science companies are subject to industry-specific risks, including but not limited to regulatory approval and clearance risk, clinical and development risk, intellectual property risk, commercialization risk, manufacturing and supply chain risk, and capital formation risk. Please review the applicable offering materials for additional information.
Investment offerings are speculative, illiquid, and involve a high degree of risk, including the possible loss of an investor's entire investment. Past performance of any security, company, project, management team, or technology is not indicative of future results.
Neither BFP nor BSI provides investment advice, recommendations, or suitability determinations. Neither BFP nor BSI provides tax, accounting, legal, or regulatory advice. Investors must make their own investment decisions and conduct their own due diligence prior to investing. The content contained herein does not constitute a solicitation of an offer to buy or sell any security.
By using this website, you agree to be bound by our Terms of Use, Privacy Policy, and Electronic Consent. Please review these carefully before using the website.
